Immuneering Added to the Nasdaq Biotechnology Index
December 16, 2021 06:50 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering Announces Participation in December Investor Conferences
November 18, 2021 06:35 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering to Participate in Jefferies 2021 London Healthcare Conference
November 10, 2021 06:50 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering Reports Third Quarter 2021 Financial Results and Recent Business Highlights
November 09, 2021 06:30 ET
|
Immuneering Corporation
Successfully completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024 Company expects to file IND for IMM-1-104 in Q1 2022 CAMBRIDGE, Mass.,...
Immuneering Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 11, 2021 06:50 ET
|
Immuneering Corporation
Preclinical Data Demonstrated Broad Antitumor Activity Across KRAS, NRAS and BRAF Mutant Tumor Models, Established Novel Mechanism of Action for its Dual MEK Inhibition and Showed Synergies with...
Immuneering to Present Key Preclinical Data Across Several Poster Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 01, 2021 06:50 ET
|
Immuneering Corporation
Preclinical Data Demonstrates Broad Antitumor Activity of IMM-1-104 Across RAS and RAF Mutant Tumors and Highlights Mechanistic Aspects of its Dual MEK Inhibition Company to Host Key Opinion Leader...
Immuneering Announces Inclusion in the Russell 2000® Index
September 20, 2021 16:10 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates
September 09, 2021 06:30 ET
|
Immuneering Corporation
Recently completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024 Company expects to file IND for IMM-1-104 in Q1 2022 CAMBRIDGE, Mass.,...
Immuneering to Participate in September Investor Conferences
September 02, 2021 16:05 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
August 03, 2021 16:07 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...